Latrepirdine
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 598435

CAS#: 3613-73-8 (free base)

Description: Latrepirdine is an orally-available drug, approved in Russia for use as a non-selective antihistamine, that has shown promise in the treatment of neurodegenerative diseases, including Alzheimer’s and Huntington’s disease. In addition to reported activity in preventing the onset and progression of disease by being neuroprotective, dimebolin appears to promote clinical improvement by increasing cognitive function. At the cellular level, dimebolin appears to have diverse effects, inhibiting the neurotoxic action of β-amyloid and blocking L-type calcium channels,5 inhibiting NMDA-type glutamate receptors, and preventing mitochondrial leakage.

Chemical Structure

img
Latrepirdine
CAS# 3613-73-8 (free base)
Product data Instruction

Theoretical Analysis

MedKoo Cat#: 598435
Name: Latrepirdine
CAS#: 3613-73-8 (free base)
Chemical Formula: C21H25N3
Exact Mass: 319.20
Molecular Weight: 319.452
Elemental Analysis: C, 78.96; H, 7.89; N, 13.15

Price and Availability

Size Price Availability Quantity
100mg USD 850 2 Weeks
200mg USD 1450 2 Weeks
500mg USD 2250 2 Weeks
1g USD 3250 2 Weeks
2g USD 5650 2 Weeks
Bulk inquiry

Related CAS #: 3613-73-8 (free base)   97657-92-6 (HCl)    

Synonym: Latrepirdine; Dimebon; Dimeboline; Dimebolin; Preparation 84;

IUPAC/Chemical Name: 2,8-dimethyl-5-(2-(6-methylpyridin-3-yl)ethyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole

InChi Key: JNODQFNWMXFMEV-UHFFFAOYSA-N

InChi Code: InChI=1S/C21H25N3/c1-15-4-7-20-18(12-15)19-14-23(3)10-9-21(19)24(20)11-8-17-6-5-16(2)22-13-17/h4-7,12-13H,8-11,14H2,1-3H3

SMILES Code: CC1=CC=C(CCN2C3=C(CN(C)CC3)C4=C2C=CC(C)=C4)C=N1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

More Info:

Product Data:
Product Data
Instruction:
View handling instruction
Biological target: Latrepirdine is an orally-available drug, approved in Russia for use as a non-selective antihistamine, that has shown promise in the treatment of neurodegenerative diseases, including Alzheimer’s and Huntington’s disease.
In vitro activity: The ability of latrepirdine to alter the formation of Aβ42 aggregates was assessed by thioflavin-T fluorescence, western immunoblotting and atomic force microscopy (AFM). Despite showing a reduction in thioflavin-T fluorescence with latrepirdine treatment, indicating a decrease in aggregation, immunoblotting and AFM showed a modest increase in both the formation and size of Aβ aggregates. The ability of latrepirdine to modulate Aβ aggregation appears to be independent of its neuroprotective effects, and is unlikely to be a mechanism by which latrepirdine offers protection. Reference: J Alzheimers Dis. 2016;50(3):895-905. https://pubmed.ncbi.nlm.nih.gov/26836170/
In vivo activity: Treatment with latrepirdine increased AMPK activity in primary mouse motor neuron cultures and in SOD1(G93A) lumbar spinal cords. Mice "preconditioned" with latrepirdine showed a delayed symptom onset and a significant increase in life span (p < 0.01). Reference: Neurobiol Aging. 2015 Feb;36(2):1140-50. https://pubmed.ncbi.nlm.nih.gov/25443289/

Preparing Stock Solutions

The following data is based on the product molecular weight 319.45 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol: 1. Porter T, Bharadwaj P, Groth D, Paxman A, Laws SM, Martins RN, Verdile G. The Effects of Latrepirdine on Amyloid-β Aggregation and Toxicity. J Alzheimers Dis. 2016;50(3):895-905. doi: 10.3233/JAD-150790. PMID: 26836170; PMCID: PMC4927897. 2. Weisová P, Alvarez SP, Kilbride SM, Anilkumar U, Baumann B, Jordán J, Bernas T, Huber HJ, Düssmann H, Prehn JH. Latrepirdine is a potent activator of AMP-activated protein kinase and reduces neuronal excitability. Transl Psychiatry. 2013 Oct 22;3(10):e317. doi: 10.1038/tp.2013.92. PMID: 24150226; PMCID: PMC3818013. 3. Coughlan KS, Mitchem MR, Hogg MC, Prehn JH. "Preconditioning" with latrepirdine, an adenosine 5'-monophosphate-activated protein kinase activator, delays amyotrophic lateral sclerosis progression in SOD1(G93A) mice. Neurobiol Aging. 2015 Feb;36(2):1140-50. doi: 10.1016/j.neurobiolaging.2014.09.022. Epub 2014 Sep 26. PMID: 25443289. 4. Steele JW, Gandy S. Latrepirdine (Dimebon®), a potential Alzheimer therapeutic, regulates autophagy and neuropathology in an Alzheimer mouse model. Autophagy. 2013 Apr;9(4):617-8. doi: 10.4161/auto.23487. Epub 2013 Feb 4. PMID: 23380933; PMCID: PMC3627679.
In vitro protocol: 1. Porter T, Bharadwaj P, Groth D, Paxman A, Laws SM, Martins RN, Verdile G. The Effects of Latrepirdine on Amyloid-β Aggregation and Toxicity. J Alzheimers Dis. 2016;50(3):895-905. doi: 10.3233/JAD-150790. PMID: 26836170; PMCID: PMC4927897. 2. Weisová P, Alvarez SP, Kilbride SM, Anilkumar U, Baumann B, Jordán J, Bernas T, Huber HJ, Düssmann H, Prehn JH. Latrepirdine is a potent activator of AMP-activated protein kinase and reduces neuronal excitability. Transl Psychiatry. 2013 Oct 22;3(10):e317. doi: 10.1038/tp.2013.92. PMID: 24150226; PMCID: PMC3818013.
In vivo protocol: 1. Coughlan KS, Mitchem MR, Hogg MC, Prehn JH. "Preconditioning" with latrepirdine, an adenosine 5'-monophosphate-activated protein kinase activator, delays amyotrophic lateral sclerosis progression in SOD1(G93A) mice. Neurobiol Aging. 2015 Feb;36(2):1140-50. doi: 10.1016/j.neurobiolaging.2014.09.022. Epub 2014 Sep 26. PMID: 25443289. 2. Steele JW, Gandy S. Latrepirdine (Dimebon®), a potential Alzheimer therapeutic, regulates autophagy and neuropathology in an Alzheimer mouse model. Autophagy. 2013 Apr;9(4):617-8. doi: 10.4161/auto.23487. Epub 2013 Feb 4. PMID: 23380933; PMCID: PMC3627679.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Chau S, Herrmann N, Ruthirakuhan MT, Chen JJ, Lanctôt KL. Latrepirdine for Alzheimer's disease. Cochrane Database Syst Rev. 2015 Apr 21;(4):CD009524. doi: 10.1002/14651858.CD009524.pub2. Review. PubMed PMID: 25897825.

2: Cano-Cuenca N, Solís-García del Pozo J, Jordán J. [Latrepirdine: a systematic review of the preclinical studies]. Rev Neurol. 2015 Jan 1;60(1):35-42. Review. Spanish. PubMed PMID: 25522862.

3: Bharadwaj PR, Bates KA, Porter T, Teimouri E, Perry G, Steele JW, Gandy S, Groth D, Martins RN, Verdile G. Latrepirdine: molecular mechanisms underlying potential therapeutic roles in Alzheimer's and other neurodegenerative diseases. Transl Psychiatry. 2013 Dec 3;3:e332. doi: 10.1038/tp.2013.97. Review. PubMed PMID: 24301650; PubMed Central PMCID: PMC4030329.

4: Porter T, Bharadwaj P, Groth D, Paxman A, Laws SM, Martins RN, Verdile G. The Effects of Latrepirdine on Amyloid-β Aggregation and Toxicity. J Alzheimers Dis. 2016;50(3):895-905. doi: 10.3233/JAD-150790. PubMed PMID: 26836170; PubMed Central PMCID: PMC4927897.

5: Weisová P, Alvarez SP, Kilbride SM, Anilkumar U, Baumann B, Jordán J, Bernas T, Huber HJ, Düssmann H, Prehn JH. Latrepirdine is a potent activator of AMP-activated protein kinase and reduces neuronal excitability. Transl Psychiatry. 2013 Oct 22;3:e317. doi: 10.1038/tp.2013.92. PubMed PMID: 24150226; PubMed Central PMCID: PMC3818013.

6: HORIZON Investigators of the Huntington Study Group and European Huntington's Disease Network. A randomized, double-blind, placebo-controlled study of latrepirdine in patients with mild to moderate Huntington disease. JAMA Neurol. 2013 Jan;70(1):25-33. doi: 10.1001/2013.jamaneurol.382. PubMed PMID: 23108692.

7: Cano-Cuenca N, Solís-García del Pozo JE, Jordán J. Evidence for the efficacy of latrepirdine (Dimebon) treatment for improvement of cognitive function: a meta-analysis. J Alzheimers Dis. 2014;38(1):155-64. doi: 10.3233/JAD-130872. PubMed PMID: 23948924.

8: Coughlan KS, Mitchem MR, Hogg MC, Prehn JH. "Preconditioning" with latrepirdine, an adenosine 5'-monophosphate-activated protein kinase activator, delays amyotrophic lateral sclerosis progression in SOD1(G93A) mice. Neurobiol Aging. 2015 Feb;36(2):1140-50. doi: 10.1016/j.neurobiolaging.2014.09.022. Epub 2014 Sep 26. PubMed PMID: 25443289.

9: Ustyugov A, Shevtsova E, Bachurin S. Novel Sites of Neuroprotective Action of Dimebon (Latrepirdine). Mol Neurobiol. 2015 Oct;52(2):970-8. doi: 10.1007/s12035-015-9249-4. Epub 2015 Jun 30. Review. PubMed PMID: 26123670.

10: Steele JW, Ju S, Lachenmayer ML, Liken J, Stock A, Kim SH, Delgado LM, Alfaro IE, Bernales S, Verdile G, Bharadwaj P, Gupta V, Barr R, Friss A, Dolios G, Wang R, Ringe D, Protter AA, Martins RN, Ehrlich ME, Yue Z, Petsko GA, Gandy S. Latrepirdine stimulates autophagy and reduces accumulation of α-synuclein in cells and in mouse brain. Mol Psychiatry. 2013 Aug;18(8):882-8. doi: 10.1038/mp.2012.115. Epub 2012 Aug 7. PubMed PMID: 22869031; PubMed Central PMCID: PMC3523214.

11: Steele JW, Gandy S. Latrepirdine (Dimebon®), a potential Alzheimer therapeutic, regulates autophagy and neuropathology in an Alzheimer mouse model. Autophagy. 2013 Apr;9(4):617-8. doi: 10.4161/auto.23487. Epub 2013 Feb 4. PubMed PMID: 23380933; PubMed Central PMCID: PMC3627679.

12: Steele JW, Lachenmayer ML, Ju S, Stock A, Liken J, Kim SH, Delgado LM, Alfaro IE, Bernales S, Verdile G, Bharadwaj P, Gupta V, Barr R, Friss A, Dolios G, Wang R, Ringe D, Fraser P, Westaway D, St George-Hyslop PH, Szabo P, Relkin NR, Buxbaum JD, Glabe CG, Protter AA, Martins RN, Ehrlich ME, Petsko GA, Yue Z, Gandy S. Latrepirdine improves cognition and arrests progression of neuropathology in an Alzheimer's mouse model. Mol Psychiatry. 2013 Aug;18(8):889-97. doi: 10.1038/mp.2012.106. Epub 2012 Jul 31. PubMed PMID: 22850627; PubMed Central PMCID: PMC3625697.

13: Bharadwaj PR, Verdile G, Barr RK, Gupta V, Steele JW, Lachenmayer ML, Yue Z, Ehrlich ME, Petsko G, Ju S, Ringe D, Sankovich SE, Caine JM, Macreadie IG, Gandy S, Martins RN. Latrepirdine (dimebon) enhances autophagy and reduces intracellular GFP-Aβ42 levels in yeast. J Alzheimers Dis. 2012;32(4):949-67. doi: 10.3233/JAD-2012-120178. PubMed PMID: 22903131; PubMed Central PMCID: PMC3529125.

14: Chew ML, Mordenti J, Yeoh T, Ranade G, Qiu R, Fang J, Liang Y, Corrigan B. Minimization of CYP2D6 Polymorphic Differences and Improved Bioavailability via Transdermal Administration: Latrepirdine Example. Pharm Res. 2016 Aug;33(8):1873-80. doi: 10.1007/s11095-016-1922-4. Epub 2016 Apr 12. PubMed PMID: 27072954.

15: Day M, Chandran P, Luo F, Rustay NR, Markosyan S, LeBlond D, Fox GB. Latrepirdine increases cerebral glucose utilization in aged mice as measured by [18F]-fluorodeoxyglucose positron emission tomography. Neuroscience. 2011 Aug 25;189:299-304. doi: 10.1016/j.neuroscience.2011.05.032. Epub 2011 May 19. PubMed PMID: 21619913.

16: Kieburtz K, McDermott MP, Voss TS, Corey-Bloom J, Deuel LM, Dorsey ER, Factor S, Geschwind MD, Hodgeman K, Kayson E, Noonberg S, Pourfar M, Rabinowitz K, Ravina B, Sanchez-Ramos J, Seely L, Walker F, Feigin A; Huntington Disease Study Group DIMOND Investigators. A randomized, placebo-controlled trial of latrepirdine in Huntington disease. Arch Neurol. 2010 Feb;67(2):154-60. doi: 10.1001/archneurol.2009.334. Erratum in: Arch Neurol. 2010 Apr;67(4):492. Dimebon in Subjects With Huntington Disease (DIMOND)Investigators of the Huntington Study Group [corrected to Huntington Disease Study Group DIMOND Investigators]. PubMed PMID: 20142523; PubMed Central PMCID: PMC4134015.

17: Sabbagh MN, Shill HA. Latrepirdine, a potential novel treatment for Alzheimer's disease and Huntington's chorea. Curr Opin Investig Drugs. 2010 Jan;11(1):80-91. Review. PubMed PMID: 20047162; PubMed Central PMCID: PMC3346261.

18: Huang Y, Yang Y, Song H, Liu Y, Wang Q. Synthesis of Structurally Diverse 2,3-Fused Indoles via Microwave-Assisted AgSbF6-Catalysed Intramolecular Difunctionalization of o-Alkynylanilines. Sci Rep. 2015 Aug 27;5:13516. doi: 10.1038/srep13516. PubMed PMID: 26310858; PubMed Central PMCID: PMC4550932.

19: Zhang S, Hedskog L, Petersen CA, Winblad B, Ankarcrona M. Dimebon (latrepirdine) enhances mitochondrial function and protects neuronal cells from death. J Alzheimers Dis. 2010;21(2):389-402. doi: 10.3233/JAD-2010-100174. PubMed PMID: 20555134.

20: Steele JW, Kim SH, Cirrito JR, Verges DK, Restivo JL, Westaway D, Fraser P, Hyslop PS, Sano M, Bezprozvanny I, Ehrlich ME, Holtzman DM, Gandy S. Acute dosing of latrepirdine (Dimebon), a possible Alzheimer therapeutic, elevates extracellular amyloid-beta levels in vitro and in vivo. Mol Neurodegener. 2009 Dec 17;4:51. doi: 10.1186/1750-1326-4-51. PubMed PMID: 20017949; PubMed Central PMCID: PMC2806870.